BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 2
• 3
• 4
• 5
• 6
• 7
• 10
• 11
• 12
• 13
• 14
• 17
• 18
• 19
• 20
• 21
• 24
• 25
• 26
• 27
• 28

• 

  Drug Development

  From Weight Loss to Hair Loss: The Search for the Next Blockbuster

  A new generation of companies is eyeing the existing, sizeable hair loss market, hoping that better formulations and new scientific targets will finally produce treatments that are safer and more effective, as well as commercially successful.

  November 10, 2025

   · 

  6 min read

   · 

  Ben Hargreaves
• 

  Cardiovascular disease

  Merck Builds Case for Cholesterol-Lowering Pill With Injectable-Like Efficacy

  Multiple analyst firms were impressed by the Phase III data, which showed that Merck’s oral PCSK9 inhibitor can lower low-density lipoprotein cholesterol by more than 55% after 24 weeks.

  November 10, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Metabolic disorders

  Lilly Makes $1.2B RNAi Pact With SangeneBio, Targets Metabolic Diseases

  Eli Lilly has been on a dealmaking spree this year, with a few deals worth $1 billion or more. Aside from SangeneBio, these include SiteOne, Verve and Scorpion.

  November 10, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Cardiovascular disease

  Amgen’s Repatha Cuts Risk of First Heart Attack by 36% in Phase III Trial

  The cholesterol-lowering drug is part of a suite of medicines that also includes MariTide and that Amgen Chief Medical Officer Paul Burton hopes will make the company the “undisputed leader in the management of cardiometabolic risk for patients” by 2030.

  November 10, 2025

   · 

  4 min read

   · 

  Heather McKenzie
• 

  Gene therapy

  Lilly Doubles Down on Eye Diseases, Adding to BD Spree

  MeiraGTx Holdings is licensing a genetic eye disease medicine to Eli Lilly in a deal worth up to $475 million.

  November 10, 2025

   · 

  1 min read

   · 

  Annalee Armstrong
• 

  Mergers & acquisitions

  Pfizer’s Winning Bid for Metsera Concludes ‘Real Housewives of Biopharma’

  The deal is done. What happens next for Pfizer and Metsera—and Novo?

  November 10, 2025

   · 

  3 min read

   · 

  Annalee Armstrong
• 

  Obesity

  Despite Obesity Drug Pricing Deal, GLP-1 Compounders Continue To Operate in the Shadows

  The White House may have struck a deal with Eli Lilly and Novo Nordisk last week to lower the costs of their weight loss drugs for patients, but knockoff versions of Zepbound and Wegovy still permeate the obesity market.

  November 10, 2025

   · 

  3 min read

   · 

  Dan Samorodnitsky
• 

  FDA

  FDA Removes Black Box Warning From HRT Products, Reversing Landmark Decision

  After a leading study caused the FDA to slap its most stringent warning on hormone replacement therapies for menopause more than two decades ago, the regulator is changing course in what FDA Commissioner Marty Makary called a “historic day for women in the United States.”

  November 10, 2025

   · 

  2 min read

   · 

  Heather McKenzie
• 

  Layoffs

  Kezar Loses 70% of Staff After FDA Cancels Meeting on Autoimmune Asset

  Kezar Life Sciences suffered multiple clinical holds and four patient deaths in a trial testing zetomipzomib for lupus—a program that has since been canned. The company is still pursuing development in autoimmune hepatitis, but recent FDA communications could delay its timeline.

  November 10, 2025

   · 

  2 min read

   · 

  Dan Samorodnitsky
• 

  Cardiovascular disease

  Ionis’ Tryngolza ‘Game-Changing’ in Lowering Triglycerides, Cementing Case for FDA Filing

  Ionis is planning a supplemental submission by the end of the year to expand Tryngolza into severe hypertriglyceridemia. If granted, William Blair expects the antisense drug to be “transformational” for this indication.

  November 10, 2025

   · 

  2 min read

   · 

  Tristan Manalac